Latest news for health care topics. Include medical news , health insurance , therapy and vaccine news

Thursday, December 1, 2016

Takeda to build $106M vaccine plant for dengue vax push quoting : fiercepharma

This content may collect you by Lucy William

We will quote to you most important and trendy news about all kind of Vaccine of the best health sites Like : "fiercepharma" and the most famous medical experts : Eric Palmer


daily : 2016-12-01 & on time : 13:8


as declared in





Takeda to build $106M vaccine plant for dengue vax push


Takeda to build $106M vaccine plant for dengue vax push
image uploaded by "fiercepharma" site
Japan's Takeda is making a big push with a vaccine for dengue and says to be prepared it will build a €100 million plant at its manufacturing site in Singen, Germany.The drugmaker announced late Tuesday that construction will begin "immediately" on the $106 million project and is slated to be complete in 2019.Takeda declined to give details on the project but did say in an email that the site in Singen has 850 employees.
about the details read more from here


Takeda plans German plant to support dengue vaccine roll-out


Takeda plans German plant to support dengue vaccine roll-out
image uploaded by "pmlive" site
Takeda is investing more than €100m in a manufacturing facility in Germany that will produce its vaccine for dengue fever.The plant in Singen is a "major step towards meeting important unmet needs in dengue prevention," according to the Japanese drugmaker, which recently started a phase III trial of its TAK-003 dengue vaccine candidate.Initial construction activities will start immediately, and the facility should be ready for production in 2019, Takeda said.
about the details read more from here


First licensed vaccine could reduce burden in regions with high-levels of dengue infection


First licensed vaccine could reduce burden in regions with high-levels of dengue infection
image uploaded by "news-medical" site
The first licensed vaccine for the potentially life-threatening dengue virus should only be used in moderate-to high impacted regions, new research has predicted.A team of international researchers, including Dr Mario Recker from the University of Exeter, have looked at the impact and cost-effectiveness of the vaccine, called Dengvaxia, under a host of varying conditions.The team found that in areas that have high-levels of dengue infection, a routine vaccination programme could reduce the burden of dengue disease on the local population by up to 25 per cent and could potentially be cost-effective in these settings.
about the details read more from here


To follow all the new news about Vaccine

No comments:

Post a Comment